Boehringer Ingelheim drops obesity drug from Gubra partnership

Boehringer Ingelheim has halted development of an obesity drug from Gubra that it originally pledged to advance back in 2017, Gubra announced in an Oct. 31 release.

Boehringer initially committed up to 250 million euros ($300 million) to partner with Gubra on obesity treatments.